Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies.